Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C60-serinol is a water-soluble C60 fullerene derivative designed as a potent antioxidant and radioprotective agent. The molecule features a C60 fullerene core functionalized with six malonate groups containing serinolamide moieties in an octahedral arrangement, which imparts high water solubility (>250 mg/ml) and low cytotoxicity compared to unmodified fullerenes. It functions as a "free radical sponge," effectively scavenging reactive oxygen species (ROS) generated by ionizing radiation, thereby preventing oxidative damage to DNA, lipids, and proteins. Developed by researchers at UTHealth Houston and MD Anderson Cancer Center, C60-serinol is being investigated as a countermeasure for astronauts against cosmic radiation and as a therapeutic to alleviate radiation-induced cardiovascular disease and other endotheliopathies in cancer patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C60-serinol.